MedWatch

Danish life science company goes public in Sweden

The Danish company 2curex has announced its arrival on Nasdaq First North in Stockholm. According to the CEO, the reason is not lack of money; the timing is simply right for the company behind the IndiTreat-technology used to identify the most effective medical treatment for cancer patients.

Foto: Colourbox

Danish biotech 2curex is about to carry out an IPO meant to bring in about DKK 14 million (USD 2.22 million), CEO Ole Thastrup says in an interview with MedWatch.

“Our company has existed for about 11 years and we think the timing is right for an IPO now, as we are about to launch the clinical validation trial on colorectal cancer,” he says.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier